Bizarre Patents
A simulation environment for the sport of boxing utilizing a robotic machine interface system which carries a person
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188060 | Duplex oligonucleotides with enhanced functionality in gene regulation Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of ... | 05/29/2012 |
| 8188062 | Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA A method of delivering an oligonucleotide or a plasmid expressing an oligonucleotide into a target cell comprises introducing an oligonucleotide into a donor cell, particularly a stem cell, and contacting the target cell with the donor cell under conditions permitti... | 05/29/2012 |
| 8188056 | Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation One aspect of the current invention is a method of preventing and/or treating arthritis and/or preventing or treating lameness in a subject. Additionally, subject quality of life and welfare, and body condition scores are improved by utilizing methodology that admin... | 05/29/2012 |
| 8183222 | Method to inhibit cell growth using oligonucleotides Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleot... | 05/22/2012 |
| 8183219 | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof The invention provides novel combination therapies for treating neurodegenerative disease which comprise a) neurotrophic factors or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The in... | 05/22/2012 |
| 8183221 | Suppression of SCN9A gene expression and/or function for the treatment of pain Disclosed herein are methods, sequences and nucleic acid molecules used to treat pain. Specifically, the methods and sequences include locally administering molecules that suppress the expression of amino acid sequences that encode for Nav1.7 channels or ... | 05/22/2012 |
| 8178506 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-codi... | 05/15/2012 |
| 8178505 | Method of predicting and reducing risk of metastasis of breast cancer to lung A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature... | 05/15/2012 |
| 8173615 | TRPM-2 antisense therapy It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of... | 05/08/2012 |
| 8173617 | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma. ... | 05/08/2012 |
| 8173614 | Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucl... | 05/08/2012 |
| 8168605 | Polymeric oligonucleotide prodrugs Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed. ... | 05/01/2012 |
| 8168608 | Promoter and plasmid system for genetic engineering This invention provides a series of low-copy number plasmids comprising restriction endonuclease recognition sites useful for cloning at least three different genes or operons, each flanked by a terminator sequence, the plasmids containing variants of glucose isomer... | 05/01/2012 |
| 8168600 | Compositions and methods for topical delivery of oligonucleotides The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids... | 05/01/2012 |
| 8168610 | Bispecific oligonucleotide for the treatment of CNS malignancies CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and whic... | 05/01/2012 |
| 8168601 | Method of delivering RNA interference and uses thereof The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the ... | 05/01/2012 |
| 8168604 | Antisense antiviral compounds and methods for treating a filovirus infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infection... | 05/01/2012 |
| 8163712 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and pept... | 04/24/2012 |
| 8163711 | Compositions and methods for inhibiting expression of the HAMP gene The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in le... | 04/24/2012 |
| 8163709 | TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS The splicing variant D of the TAK1 gene is activated by short double-stranded RNAs in a sequence specific manner. Activation of TAK1-D leads to the downstream activation of the p38 MAPK and of SAPK/JNK but not the NFκB pathway. The current invention therefore provi... | 04/24/2012 |
| 8158595 | Modular aptamer-regulated ribozymes An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, c... | 04/17/2012 |
| 8158599 | Chimeric adenoviruses for use in cancer treatment The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral s... | 04/17/2012 |
| 8158601 | Lipid formulation The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. ... | 04/17/2012 |
| 8153607 | Transcription factor decoys and use thereof A pharmaceutical composition having a transcription factor decoy and a pharmaceutical acceptable carrier thereof is provided, wherein the transcription factor decoy is TCF decoy. A method for curing or preventing endotoxin-treated endothelial cells from apoptosis is... | 04/10/2012 |
| 8153608 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune res... | 04/10/2012 |
| 8153602 | Composition and methods for the pulmonary delivery of nucleic acids The present invention relates to compositions and methods for the pulmonary delivery of nucleic acids, particularly oligonucleotides. In one preferred embodiment, the compositions and methods of the invention are utilized to effect the pulmonary delivery of an antis... | 04/10/2012 |
| 8153603 | Compositions and their uses directed to IL-4R alpha Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a ... | 04/10/2012 |
| 8153606 | Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1 Oligonucleotide compounds modulate expression and/or function of an apolipoprotein (ApoA1) polynucleotides and encoded products thereof. Methods for treating diseases associated with apolipoprotein-A1 (ApoA1) comprise administering one or more Oligonucleotide compou... | 04/10/2012 |
| 8148341 | Method for modulating responsiveness to steroids The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of a... | 04/03/2012 |
| 8148342 | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the... | 04/03/2012 |
| 8148345 | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression. ... | 04/03/2012 |
| 8148346 | Compositions and methods for the systemic treatment of arthritis The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at l... | 04/03/2012 |
| 8148347 | Inhibition of interaction of PSD93 and PSDS95 with nNOS and NMDA receptors PSD-95/SAP90 antisense-treated animals not only experience a significant decrease in MAC for isoflurane, but also experience an attenuation in the NMDA-induced increase in isoflurane MAC. PSD-95/SAP90 appears to mediate the role of the NMDA receptor in determining t... | 04/03/2012 |
| 8143232 | Gene fusion targeted therapy The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer. ... | 03/27/2012 |
| 8143231 | Method of reducing HIV-replication in human body tissue Mononuclear phagocytes are reservoirs, vehicles of dissemination, and targets for persistent HIV infection. However, not all MP population equally support viral growth. Such differential replication is typified by the greater ability of placental macrophages (PM), a... | 03/27/2012 |
| 8138161 | Modified small interfering RNA molecules and methods of use The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which i... | 03/20/2012 |
| 8133876 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-codi... | 03/13/2012 |
| 8129356 | Bmx mediated signal transduction in irradiated vascular endothelium Provided are methods for modulating the proliferation of cells and tissues. In some embodiments, the methods include administering to a subject an effective amount of a modulator of a biological activity of a bone marrow X kinase (Bmx) gene product. Also provided ar... | 03/06/2012 |
| 8129352 | Antisense antiviral compound and method for treating ssRNA viral infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in th... | 03/06/2012 |
| 8129354 | Treatment of neurological disorders by dsRNA administration The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein the dsRNA inhibits the expression of a target gene and to pharmaceutical co... | 03/06/2012 |
